Structure Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
Cayman Islands
Business Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
Phone
(650) 457-1978
Fiscal Year End
1231
EIN
981480821
Financial Overview
FY2025
-$89.62M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Lead candidate GSBR-1290 (oral GLP-1R agonist) showed promising Phase 2a data for obesity/Type 2 Diabetes, preparing for Phase 2b in Q2 2026.
- ANPA-0073 (oral Apelin Receptor Agonist) for heart failure advanced into Phase 1 clinical trials in mid-2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.